Indication Expansion Strategy for Biotech Assets and Platforms
Scan, assess, and sequence indication opportunities with scientific rationale, clinical feasibility, competitive density, IP context, market structure, and valuation logic.
Decision questions
What this solution is built to answer.
Which indications should enter the shortlist and why?
Which opportunities have biological rationale but poor commercial or clinical feasibility?
How should a platform sequence indications under capital constraints?
Which candidates deserve go, hold, kill, or deeper assessment?
Capabilities
What ARiDA can run for this use case.
Broad indication scan across 10-30 candidates.
Deep assessment of a 3-5 indication shortlist.
Board-grade expansion roadmap for the final 1-2 indications.
Scientific, commercial, competitive, regulatory, IP, and valuation scoring lanes.
Target-indication matrix script for repeatable scoring visuals.
Workflow table
Named workflows and expected artifacts.
| Workflow | Role | Artifacts |
|---|---|---|
| indication-expansion-scan | Broad-universe triage | INDICATION__SCAN, target-indication matrix, shortlist |
| indication-expansion-assessment | Deep per-indication assessment | INDICATION__ASSESSMENT with score and verdict |
| indication-expansion-strategy | Board-ready sequencing and roadmap | INDICATION__STRATEGY_DOSSIER, roadmap, risk register |
Evidence inputs
Data sources, tools, and user context.
Outputs
What the workflow should leave behind.
Deliverables
Ranked indication shortlist.
Target-indication scoring matrix.
Per-indication evidence and caveat table.
Expansion roadmap with investment plan and sequencing logic.
Proof points
Indication workflows are split into scan, assessment, and strategy tiers.
The workflow can combine biology, trials, IP, regulatory, competition, and valuation rather than ranking on one dimension.
The scoring matrix is backed by a reusable script path.
FAQ
Common evaluation questions.
Is indication expansion just market sizing?
Market size matters, but ARiDA also stages biological rationale, clinical feasibility, competitive density, IP context, regulatory path, and valuation implications.
Can a broad scan become a board roadmap?
Yes. The workflow family is tiered so broad scans can move into deep assessment and then into an expansion strategy dossier.
Related solutions
Clinical Trial Intelligence
Analyze trial landscapes, protocol patterns, endpoints, enrollment signals, sponsor behavior, recent registry changes, and historical AACT structure.
Systematic Review
Run PRISMA-style biomedical literature reviews with PubMed and PMC search lanes, screening logic, evidence tables, certainty summaries, and durable review artifacts.
Biotech Valuation
ARiDA runs evidence-backed biotech valuation workflows across single assets, multi-asset portfolios, platforms, fundraises, real options, Monte Carlo risk, and board dossiers.
Related reading
How to Evaluate Indication Expansion Opportunities
The whiteboard always shows more opportunities than the portfolio can support. Good strategy makes defensible cuts under uncertainty.
From Prompt to Board-Ready Dossier
A board-ready dossier is the visible edge of a research package strong enough to survive second-order questions.
How to Triage a Portfolio Into Go / Hold / Kill Decisions
Portfolio triage is painful for a reason: it forces the organization to compare stories it would rather evaluate one by one.